C4 Therapeutics is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. Co.'s primary advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3 in clinical development for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable Bifunctional Degradation Activating Compounds degrader of a protein target called BRD9, for synovial sarcoma and SMARCB1-deleted solid tumors. The CCCC stock yearly return is shown above.
The yearly return on the CCCC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CCCC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|